Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
EntreMed |
---|---|
Information provided by: | EntreMed |
ClinicalTrials.gov Identifier: | NCT00049790 |
The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein administered in combination with paclitaxel and carboplatin to patients with non-small-cell lung cancer.
Condition | Intervention | Phase |
---|---|---|
Carcinoma, Non-Small-Cell Lung |
Drug: recombinant human Angiostatin protein Drug: paclitaxel Drug: carboplatin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion:
Exclusion:
Study ID Numbers: | ANG-CL-004 |
Study First Received: | November 13, 2002 |
Last Updated: | January 8, 2009 |
ClinicalTrials.gov Identifier: | NCT00049790 |
Health Authority: | United States: Food and Drug Administration |
Advanced non-small cell lung cancer |
Thoracic Neoplasms Non-small cell lung cancer Respiratory Tract Diseases Paclitaxel Lung Neoplasms Lung Diseases |
Carboplatin Angiostatins Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Respiratory Tract Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Growth Substances Physiological Effects of Drugs Mitosis Modulators Antimitotic Agents Angiogenesis Inhibitors |
Pharmacologic Actions Neoplasms Neoplasms by Site Therapeutic Uses Tubulin Modulators Growth Inhibitors Angiogenesis Modulating Agents Antineoplastic Agents, Phytogenic |